



## SUPPLEMENTARY DATA


A



B




**Figure 1S.** Representative amplification curves of ExBP-RT assay using single RNA templates. (A) qPCR amplification curves of mutant KRAS G12R RNA only (from left to right)  $10^8$ ,  $10^7$ ,  $10^6$ ,  $10^5$ ,  $10^4$ ,  $10^3$ ,  $H_2O$ . (B) qPCR amplification curves of wildtype KRAS RNA only (from left to right)  $10^8$ ,  $10^7$ . An extendable blocking probe was used in reverse transcription to suppress amplification of the wildtype KRAS RNA template. Due to cross-reactivity in reverse transcription, some amplification occurred in samples containing more than  $10^7$  copies of wildtype template. Samples containing  $10^6$  copies or less of wildtype KRAS RNA show no amplification.




**Figure 2S.** Visualization of ExBP-RT amplification products on agarose gel 2%. The expected size (59 bp) of specific amplified sequences has been confirmed after 42 cycles of PCR for all ExBP-RT assays containing  $10^8$ ,  $10^7$ ,  $10^6$ ,  $10^5$ ,  $10^4$ ,  $10^3$  copies of mutant KRAS G12R RNA (lanes 3-8, respectively) and those assays containing  $10^8$ ,  $10^7$  copies of wildtype KRAS RNA (lanes 13,14, respectively). No specific amplification product has been detected on gel for assays containing lower copy numbers of wildtype KRAS RNA ( $10^6$ ,  $10^5$ ,  $10^4$ ,  $10^3$  copies, corresponding to lanes 15,16,17,18) or H<sub>2</sub>O (lane 9). Lanes 1 and 11 are GeneRuler 50bp DNA ladder, ready-to-use (Thermo Scientific). Lanes 2,10 and 12 are blank wells.


A




B



**Figure 3S:** ASB-PCR assay (Mut2.1) for detection of mutant KRAS G12D RNA. A) Representative qPCR amplification curves of serial dilution and linear regression analysis showing a compromised PCR efficiency of only 90%. B) qPCR amplification curves derived from the same copy number of either mutant transcript (left curves) or wildtype transcript (right curves).




**Figure 4S:** Relative quantification of total amount of KRAS RNA from different clinical samples. Total amount of KRAS RNA from each clinical sample was quantified using a qPCR assay targeting a fragment upstream of the mutation site, which amplifies both the mutant and wildtype cDNA resulted from ExBP-RT assay. All tested samples showed comparable amount of total KRAS RNA with the Ct values ranging from 29.0 to 30.7 ( $0.6 - 1.8 \times 10^5$  copies/500ng of total RNA), in which the Ct value corresponding to the tested mutation-positive sample is 29.8. Primer and probe sequences and their concentration used in this qPCR assay are: KRAS-Up/Fw: 5' - AGGCCTGCTGAAAATGACTG -3' (0.6  $\mu$ M); KRAS-Up/Rv: 5' - GCTCCAACCTACCACAAG - 3' (0.6  $\mu$ M); and KRAS-Up/P : FAM-AGAGGCTCAGCGGCTCCCAG - BHQ1 (0.4  $\mu$ M)




**Figure 5S.** Visualization of ExBP-RT amplification products derived from FFPE clinical samples on agarose gel 2%. The expected size (59 bp) of specific amplified sequences has been confirmed for both the positive control (lane 3) and the positive-tested sample (lane 9 - sample #5). No specific amplification product has been detected on gel for all negative-tested samples (sample #1-4 and #6-11) as well as the negative control without template. Lanes 1 is GeneRuler 50bp DNA ladder, ready-to-use (Thermo Scientific). Lanes 2 is blank well.

A.



B.

**Figure 6S:** Quantification of total KRAS RNA from different clinical samples in multiplex ExBP-RT assay. Total amount of KRAS RNA from each clinical sample was quantified using a qPCR assay targeting a fragment upstream of the mutation site, which amplifies both the mutant and wildtype cDNA resulted from ExBP-RT assay. All KRAS mutation positive-tested samples (A) and negative-tested samples (B) showed comparable amount of total KRAS RNA.



**Figure 7S.** qPCR amplification curves derived from the same copy number ( $10^8$  copies) of either mutant KRAS G12D transcripts (left curves) or another mutant variant, KRAS G12A transcript as a wildtype surrogate (right curves). cDNA synthesis reactions were performed following the same protocol described in the Methods section. The sequence of the Extendable competitive Blocking Probe is 5'-GCCAGCAGC-3', which is fully complementary to the mutant KRAS G12A RNA. The resulting  $\Delta C_{t_{wt-mt}}$  of this ExBP-RT assay is 11.01 cycles, corresponding to an excellent selectivity of 0.05%.